- Home
- TWFG vs ABVX Comparison
TWFG vs ABVX Comparison
Compare TWFG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- ABVX
- Stock Information
- Founded
- TWFG 2001
- ABVX 2013
- Country
- TWFG United States
- ABVX France
- Employees
- TWFG N/A
- ABVX N/A
- Industry
- TWFG
- ABVX
- Sector
- TWFG
- ABVX
- Exchange
- TWFG NYSE
- ABVX Nasdaq
- Market Cap
- TWFG 437.4M
- ABVX 378.7M
- IPO Year
- TWFG 2024
- ABVX N/A
- Fundamental
- Price
- TWFG $33.38
- ABVX $6.50
- Analyst Decision
- TWFG Buy
- ABVX Strong Buy
- Analyst Count
- TWFG 8
- ABVX 7
- Target Price
- TWFG $33.00
- ABVX $37.29
- AVG Volume (30 Days)
- TWFG 112.2K
- ABVX 153.8K
- Earning Date
- TWFG 05-15-2025
- ABVX 03-24-2025
- Dividend Yield
- TWFG N/A
- ABVX N/A
- EPS Growth
- TWFG N/A
- ABVX N/A
- EPS
- TWFG 0.19
- ABVX N/A
- Revenue
- TWFG $203,760,000.00
- ABVX $11,172,999.00
- Revenue This Year
- TWFG $22.41
- ABVX $371.31
- Revenue Next Year
- TWFG $20.43
- ABVX N/A
- P/E Ratio
- TWFG $179.69
- ABVX N/A
- Revenue Growth
- TWFG 18.44
- ABVX 135.94
- 52 Week Low
- TWFG $21.31
- ABVX $4.77
- 52 Week High
- TWFG $36.50
- ABVX $16.63
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- ABVX 53.63
- Support Level
- TWFG N/A
- ABVX $5.89
- Resistance Level
- TWFG N/A
- ABVX $6.75
- Average True Range (ATR)
- TWFG 0.00
- ABVX 0.60
- MACD
- TWFG 0.00
- ABVX 0.11
- Stochastic Oscillator
- TWFG 0.00
- ABVX 87.37
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.